<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01533935</url>
  </required_header>
  <id_info>
    <org_study_id>1237.14</org_study_id>
    <secondary_id>2011-004660-30</secondary_id>
    <nct_id>NCT01533935</nct_id>
  </id_info>
  <brief_title>Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.</brief_title>
  <official_title>A Randomised, Double-blind, 5 Treatment Arms, 4-period, Incomplete Cross-over Study to Determine the Effect of 6 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (FDC) (2.5 / 5 µg; and 5 / 5 µg) (Delivered by the Respimat® Inhaler) Compared With Tiotropium (5 µg), Olodaterol (5 µg ) and Placebo (Delivered by the Respimat® Inhaler) on Lung Hyperinflation and Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD) [MORACTO TM 2]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to investigate the effect of 6 weeks treatment with
      tiotropium + olodaterol fixed dose combination inhalation solution on lung hyperinflation and
      exercise tolerance in patients with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inspiratory Capacity at Rest Before Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Work Capacity</measure>
    <time_frame>6 weeks</time_frame>
    <description>Inspiratory capacity (IC) at rest before constant work rate cycle ergometry to symptom limitation at 75% maximal work capacity (Wcap).
Wcap was defined as the maximum work rate achieved for at least 30 seconds during the incremental cycle ergometry performed at Visit 1.
The presented means are adjusted means from the MMRM (Mixed Effects Model Repeated Measures) model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endurance Time During Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap</measure>
    <time_frame>6 weeks</time_frame>
    <description>Endurance time during constant work rate cycle ergometry (CWRCE) to symptom limitation at 75% Wcap
Wcap was defined as the maximum work rate achieved for at least 30 seconds during the incremental cycle ergometry performed at Visit 1.
The presented means are adjusted mean from the MMRM model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Slope of the Intensity of Breathing Discomfort (Borg Scale) During Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap</measure>
    <time_frame>6 weeks</time_frame>
    <description>Slope of the intensity of breathing discomfort (Borg Scale) during CWRCE to symptom limitation at 75% Wcap. The intensity of breathing discomfort was rated using the modified Borg scale with ratings from 0 (nothing at all) to 10 (maximal).
Slope is defined as : (intensity of breathing discomfort at the end of exercise minus intensity of breathing discomfort at rest) / endurance time.
A decrease in slope indicates improvement.
The presented means are adjusted means from MMRM model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (1 Hour Post-dose)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Forced Expiratory Volume in 1 Second (FEV1) (one hour post-dose).
The presented means are adjusted means from MMRM model.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">291</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Olodaterol 5 mcg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient will receive olodaterol 5 mcg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator for tiotropium + olodaterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium 5 mcg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient will receive tiotropium 5 mcg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium + olodaterol low dose QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in fixed dose combination once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium + olodaterol high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo matching tiotropium + olodaterol</description>
    <arm_group_label>Placebo QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium + Olodaterol</intervention_name>
    <description>Tiotropium 2.5 mcg + olodaterol 5 mcg once daily</description>
    <arm_group_label>Tiotropium + olodaterol low dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium + Olodaterol</intervention_name>
    <description>tiotropium 5 mcg + olodaterol 5 mcg once daily</description>
    <arm_group_label>Tiotropium + olodaterol high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>tiotropium</description>
    <arm_group_label>Tiotropium 5 mcg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol</intervention_name>
    <description>Olodaterol 5 mcg once daily</description>
    <arm_group_label>Olodaterol 5 mcg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <description>Respimat inhaler</description>
    <arm_group_label>Olodaterol 5 mcg QD</arm_group_label>
    <arm_group_label>Placebo QD</arm_group_label>
    <arm_group_label>Tiotropium 5 mcg QD</arm_group_label>
    <arm_group_label>Tiotropium + olodaterol low dose QD</arm_group_label>
    <arm_group_label>Tiotropium + olodaterol high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. All patients must sign an informed consent consistent with ICH-GCP guidelines prior to
             participation in the trial, which includes medication washout and restrictions.

          2. All patients must have a diagnosis of chronic obstructive pulmonary disease and must
             meet the following spirometric criteria:

             Patients must have relatively stable airway obstruction with a post-bronchodilator
             FEV1 &lt;80% of predicted normal and a post-bronchodilator FEV1/FVC &lt;70% at Visit 1.

          3. Male or female patients, between 40 and 75 years of age (inclusive) on day of signing
             informed consent.

          4. Patients must be current or ex-smokers with a smoking history of more than 10 pack
             years.

        Exclusion criteria:

          1. Patients with a significant disease other than COPD; a significant disease is defined
             as a disease which, in the opinion of the investigator, may (i) put the patient at
             risk because of participation in the study, (ii) influence the results of the study,
             or (iii) cause concern regarding the patient's ability to participate in the study

          2. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or
             urinalysis; all patients with an SGOT &gt;x2 ULN, SGPT &gt;x2 ULN, bilirubin &gt;x2 ULN or
             creatinine &gt;x2 ULN will be excluded regardless of clinical condition

          3. Patients with a history of asthma. For patients with allergic rhinitis or atopy,
             source documentation is required to verify that the patient does not have asthma.

             Patients with any of the following conditions:

          4. A diagnosis of thyrotoxicosis (due to the known class side effect profile of
             ß2-agonists)

          5. A diagnosis of paroxysmal tachycardia (&gt;100 beats per minute) (due to the known class
             side effect profile of ß2-agonists)

          6. A history of myocardial infarction within 1 year of screening visit (Visit 1)

          7. Unstable or life-threatening cardiac arrhythmia

          8. Hospitalized for heart failure within the past year

          9. Known active tuberculosis

         10. A malignancy for which patient has undergone resection, radiation therapy or
             chemotherapy within last five years (patients with treated basal cell carcinoma are
             allowed)

         11. A history of life-threatening pulmonary obstruction

         12. A history of cystic fibrosis

         13. Clinically evident bronchiectasis

         14. A history of significant alcohol or drug abuse

         15. Any contraindications for exercise testing.

         16. Patients who have undergone thoracotomy with pulmonary resection (patients with a
             history of thoracotomy for other reasons should be evaluated as per exclusion
             criterion No. 1)

         17. Patients being treated with any oral ß-adrenergics

         18. Patients being treated with oral corticosteroid medication at unstable doses

         19. Patients who regularly use daytime oxygen therapy for more than one hour per day and
             in the investigator's opinion will be unable to abstain from the use of oxygen therapy
             during clinic visits

         20. Patients who have completed a pulmonary rehabilitation program in the six weeks prior
             to the screening visit or patients who are currently in a pulmonary rehabilitation
             program

         21. Patients who have a limitation of exercise performance as a result of factors other
             than fatigue or exertional dyspnoea, such as arthritis in the leg, angina pectoris or
             claudication or morbid obesity.

         22. Patients who have taken an investigational drug within one month or six half lives
             (whichever is greater) prior to screening visit

         23. Patients with known hypersensitivity to ß-adrenergics drugs, anticholinergic drugs,
             BAC, EDTA or any other component of the Respimat® inhalation solution delivery system

         24. Pregnant or nursing women

         25. Women of childbearing potential not using highly effective methods of birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1237.14.01404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.01414 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.01417 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.01418 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.01408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.01409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.01407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.01403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.01401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.01412 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.01410 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.54402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.54401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.43402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grieskirchen</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.43401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neumarkt am Wallersee</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.11404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.11403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.11402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.11401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.49406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.49404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.49401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.49405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.49403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.49402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.31006 Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.31007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.70401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.70402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.14.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Colombia</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2012</study_first_posted>
  <results_first_submitted>June 19, 2015</results_first_submitted>
  <results_first_submitted_qc>August 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2015</results_first_posted>
  <disposition_first_submitted>April 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 16, 2014</disposition_first_posted>
  <last_update_submitted>August 12, 2015</last_update_submitted>
  <last_update_submitted_qc>August 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a randomised, 4-period incomplete block cross-over trial. 291 patients were randomized to one of five treatments sequences and treated. It was a double-blind trial in which each treatment period lasted 6 weeks with a washout period of 21 days between each.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tio+Olo 2.5/5 / Tio+Olo 5/5 / Tio / Olo</title>
          <description>Patients received a total of four treatments, and each treatment period is separated by a washout period of 21 days. The treatments administered, by oral inhalation delivered once daily in the morning, via the respimat inhaler, were
Fixed dose combination (FDC) of Tiotropium 2.5 µg and Olodaterol 5 µg.
Fixed dose combination (FDC) of Tiotropium 5 µg and Olodaterol 5 µg
Tiotropium fixed dose 5 µg
Olodaterol fixed dose 5 µg</description>
        </group>
        <group group_id="P2">
          <title>Tio+Olo 5/5 / Tio / Olo / Placebo</title>
          <description>Patients received a total of four treatments, and each treatment period is separated by a washout period of 21 days. The treatments administered, by oral inhalation delivered once daily in the morning, via the respimat inhaler, were
Fixed dose combination (FDC) of Tiotropium 5 µg and Olodaterol 5 µg
Tiotropium fixed dose 5 µg
Olodaterol fixed dose 5 µg
Oral inhalation of placebo</description>
        </group>
        <group group_id="P3">
          <title>Tio / Olo / Placebo / Tio+Olo 2.5/5</title>
          <description>Patients received a total of four treatments, and each treatment period is separated by a washout period of 21 days. The treatments administered, by oral inhalation delivered once daily in the morning, via the respimat inhaler, were
Tiotropium fixed dose 5 µg
Olodaterol fixed dose 5 µg
Oral inhalation of placebo
Fixed dose combination (FDC) of Tiotropium 2.5 µg and Olodaterol 5 µg</description>
        </group>
        <group group_id="P4">
          <title>Olo / Placebo / Tio+Olo 2.5/5 / Tio+Olo 5/5</title>
          <description>Patients received a total of four treatments, and each treatment period is separated by a washout period of 21 days. The treatments administered, by oral inhalation delivered once daily in the morning, via the respimat inhaler, were
Olodaterol fixed dose 5 µg
Oral inhalation of placebo
Fixed dose combination (FDC) of Tiotropium 2.5 µg and Olodaterol 5 µg
Fixed dose combination (FDC) of Tiotropium 5 µg and Olodaterol 5 µg</description>
        </group>
        <group group_id="P5">
          <title>Placebo / Tio+Olo 2.5/5 / Tio+Olo 5/5 / Tio</title>
          <description>Patients received a total of four treatments, and each treatment period is separated by a washout period of 21 days. The treatments administered, by oral inhalation delivered once daily in the morning, via the respimat inhaler, were
Oral inhalation of placebo
Fixed dose combination (FDC) of Tiotropium 2.5 µg and Olodaterol 5 µg
Fixed dose combination (FDC) of Tiotropium 5 µg and Olodaterol 5 µg
Tiotropium fixed dose 5 µg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="59"/>
                <participants group_id="P5" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Placebo</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="57"/>
                <participants group_id="P5" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Olo 5</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="59"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Tio 5</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Tio+Olo 2.5/5</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="56"/>
                <participants group_id="P5" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Tio+Olo 5/5</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="1">One patient received Tio+Olo 5/5 instead of Tio+Olo 2.5/5 by mistake.</participants>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52">All treatment periods</participants>
                <participants group_id="P2" count="45">All treatment periods</participants>
                <participants group_id="P3" count="50">All treatment periods</participants>
                <participants group_id="P4" count="52">All treatment periods</participants>
                <participants group_id="P5" count="50">All treatment periods</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS) : This patient set included all patients of the Randomised Set (RS : patients who signed the informed consent form and were also randomised, regardless of whether the patient was treated with study medication or not) who were dispensed study medication and were documented to have taken at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>A randomised, double-blind, placebo controlled, 5 treatment, 4-period, incomplete, crossover study. Each treatment period was separated by a washout period of 21 days. The treatments administered, by oral inhalation delivered once daily in the morning, via the respimat inhaler, were:
Oral inhalation of placebo
Tiotropium fixed dose 5 µg
Olodaterol fixed dose 5 µg
Fixed dose combination (FDC) of Tiotropium 2.5 µg and Olodaterol 5 µg
Fixed dose combination (FDC) of Tiotropium 5 µg and Olodaterol 5 µg
Treatment sequence is not considered as a factor which may affect the treatment effect due to sufficient washout period added between treatment cycles. As a result, we only display baseline characteristics as a whole population, but not by treatment sequence</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="291"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.2" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inspiratory Capacity at Rest Before Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Work Capacity</title>
        <description>Inspiratory capacity (IC) at rest before constant work rate cycle ergometry to symptom limitation at 75% maximal work capacity (Wcap).
Wcap was defined as the maximum work rate achieved for at least 30 seconds during the incremental cycle ergometry performed at Visit 1.
The presented means are adjusted means from the MMRM (Mixed Effects Model Repeated Measures) model.</description>
        <time_frame>6 weeks</time_frame>
        <population>Full Analysis Set (FAS) : This patient set included all patients in the TS who had the study baseline and at least 1 evaluable post-dose measurement for 1 of the primary endpoints. Assignment to the FAS was done after implementation of any data handling rules,which set measurements to missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of placebo, 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 5 µg</title>
            <description>Oral inhalation of Olodaterol fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5 µg</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium + Olodaterol 2.5/5</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 µg and Olodaterol 5 µg (Tiotropium: 1.25 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium + Olodaterol 5/5</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity at Rest Before Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Work Capacity</title>
          <description>Inspiratory capacity (IC) at rest before constant work rate cycle ergometry to symptom limitation at 75% maximal work capacity (Wcap).
Wcap was defined as the maximum work rate achieved for at least 30 seconds during the incremental cycle ergometry performed at Visit 1.
The presented means are adjusted means from the MMRM (Mixed Effects Model Repeated Measures) model.</description>
          <population>Full Analysis Set (FAS) : This patient set included all patients in the TS who had the study baseline and at least 1 evaluable post-dose measurement for 1 of the primary endpoints. Assignment to the FAS was done after implementation of any data handling rules,which set measurements to missing.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="208"/>
                <count group_id="O4" value="212"/>
                <count group_id="O5" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.502" spread="0.026"/>
                    <measurement group_id="O2" value="2.687" spread="0.025"/>
                    <measurement group_id="O3" value="2.679" spread="0.025"/>
                    <measurement group_id="O4" value="2.776" spread="0.025"/>
                    <measurement group_id="O5" value="2.767" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.265</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.215</ci_lower_limit>
            <ci_upper_limit>0.315</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 5/5 QD minus Placebo QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.080</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.031</ci_lower_limit>
            <ci_upper_limit>0.129</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 5/5 QD minus Olodaterol 5 mcg QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.088</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.137</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 5/5 QD minus Tiotropium 5 mcg QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.274</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.224</ci_lower_limit>
            <ci_upper_limit>0.324</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 2.5/5 QD minus Placebo QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.089</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.138</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 2.5/5 QD minus Olodaterol 5 mcg QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.097</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.047</ci_lower_limit>
            <ci_upper_limit>0.147</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 2.5/5 QD minus Tiotropium 5 mcg QD</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endurance Time During Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap</title>
        <description>Endurance time during constant work rate cycle ergometry (CWRCE) to symptom limitation at 75% Wcap
Wcap was defined as the maximum work rate achieved for at least 30 seconds during the incremental cycle ergometry performed at Visit 1.
The presented means are adjusted mean from the MMRM model.</description>
        <time_frame>6 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of placebo, 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 5 µg</title>
            <description>Oral inhalation of Olodaterol fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5 µg</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium + Olodaterol 2.5/5</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 µg and Olodaterol 5 µg (Tiotropium: 1.25 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium + Olodaterol 5/5</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Endurance Time During Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap</title>
          <description>Endurance time during constant work rate cycle ergometry (CWRCE) to symptom limitation at 75% Wcap
Wcap was defined as the maximum work rate achieved for at least 30 seconds during the incremental cycle ergometry performed at Visit 1.
The presented means are adjusted mean from the MMRM model.</description>
          <population>FAS</population>
          <units>seconds</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="209"/>
                <count group_id="O4" value="212"/>
                <count group_id="O5" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410.77" spread="12.009"/>
                    <measurement group_id="O2" value="419.06" spread="12.207"/>
                    <measurement group_id="O3" value="446.50" spread="12.958"/>
                    <measurement group_id="O4" value="460.66" spread="13.310"/>
                    <measurement group_id="O5" value="465.68" spread="13.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.134</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.065</ci_lower_limit>
            <ci_upper_limit>1.206</ci_upper_limit>
            <estimate_desc>Ratio calculated as Tiotropium + olodaterol 5/5 QD divided by Placebo QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.045</ci_lower_limit>
            <ci_upper_limit>1.182</ci_upper_limit>
            <estimate_desc>Ratio calculated Tiotropium + olodaterol 5/5 QD as divided by Olodaterol 5 mcg QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1807</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.043</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.033</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.981</ci_lower_limit>
            <ci_upper_limit>1.109</ci_upper_limit>
            <estimate_desc>Ratio calculated as Tiotropium + olodaterol 5/5 QD divided by Tiotropium 5 mcg QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.121</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.054</ci_lower_limit>
            <ci_upper_limit>1.193</ci_upper_limit>
            <estimate_desc>Ratio calculated as Tiotropium + olodaterol 2.5/5 QD divided by Placebo QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.033</ci_lower_limit>
            <ci_upper_limit>1.170</ci_upper_limit>
            <estimate_desc>Ratio calculated as Tiotropium + olodaterol 2.5/5 QD divided by Olodaterol 5 mcg QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3240</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.032</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.033</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.970</ci_lower_limit>
            <ci_upper_limit>1.098</ci_upper_limit>
            <estimate_desc>Ratio calculated as Tiotropium + olodaterol 2.5/5 QD divided by Tiotropium 5 mcg QD</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Slope of the Intensity of Breathing Discomfort (Borg Scale) During Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap</title>
        <description>Slope of the intensity of breathing discomfort (Borg Scale) during CWRCE to symptom limitation at 75% Wcap. The intensity of breathing discomfort was rated using the modified Borg scale with ratings from 0 (nothing at all) to 10 (maximal).
Slope is defined as : (intensity of breathing discomfort at the end of exercise minus intensity of breathing discomfort at rest) / endurance time.
A decrease in slope indicates improvement.
The presented means are adjusted means from MMRM model.</description>
        <time_frame>6 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of placebo, 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 5 µg</title>
            <description>Oral inhalation of Olodaterol fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5 µg</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium + Olodaterol 2.5/5</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 µg and Olodaterol 5 µg (Tiotropium: 1.25 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium + Olodaterol 5/5</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Slope of the Intensity of Breathing Discomfort (Borg Scale) During Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap</title>
          <description>Slope of the intensity of breathing discomfort (Borg Scale) during CWRCE to symptom limitation at 75% Wcap. The intensity of breathing discomfort was rated using the modified Borg scale with ratings from 0 (nothing at all) to 10 (maximal).
Slope is defined as : (intensity of breathing discomfort at the end of exercise minus intensity of breathing discomfort at rest) / endurance time.
A decrease in slope indicates improvement.
The presented means are adjusted means from MMRM model.</description>
          <population>FAS</population>
          <units>units on a scale / s</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="208"/>
                <count group_id="O4" value="212"/>
                <count group_id="O5" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" spread="0.001"/>
                    <measurement group_id="O2" value="0.017" spread="0.001"/>
                    <measurement group_id="O3" value="0.015" spread="0.001"/>
                    <measurement group_id="O4" value="0.014" spread="0.001"/>
                    <measurement group_id="O5" value="0.015" spread="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.001</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>-0.002</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 5/5 QD minus Placebo QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0033</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.002</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.001</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.003</ci_lower_limit>
            <ci_upper_limit>-0.001</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 5/5 QD minus Olodaterol 5 mcg QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2306</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.001</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.001</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.002</ci_lower_limit>
            <ci_upper_limit>0.001</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 5/5 QD minus Tiotropium 5 mcg QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.001</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>-0.002</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 2.5/5 QD minus Placebo QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.002</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.001</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>-0.001</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 2.5/5 QD minus Olodaterol 5 mcg QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1206</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.001</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.001</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.002</ci_lower_limit>
            <ci_upper_limit>0.000</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 2.5/5 QD minus Tiotropium 5 mcg QD</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 (1 Hour Post-dose)</title>
        <description>Forced Expiratory Volume in 1 Second (FEV1) (one hour post-dose).
The presented means are adjusted means from MMRM model.</description>
        <time_frame>6 weeks</time_frame>
        <population>All patients in FAS with available FEV1 data at baseline and week 6 are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of placebo, 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 5 µg</title>
            <description>Oral inhalation of Olodaterol fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5 µg</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium + Olodaterol 2.5/5</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 µg and Olodaterol 5 µg (Tiotropium: 1.25 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium + Olodaterol 5/5</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (1 Hour Post-dose)</title>
          <description>Forced Expiratory Volume in 1 Second (FEV1) (one hour post-dose).
The presented means are adjusted means from MMRM model.</description>
          <population>All patients in FAS with available FEV1 data at baseline and week 6 are included in the analysis.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="211"/>
                <count group_id="O4" value="215"/>
                <count group_id="O5" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.548" spread="0.016"/>
                    <measurement group_id="O2" value="1.742" spread="0.016"/>
                    <measurement group_id="O3" value="1.741" spread="0.016"/>
                    <measurement group_id="O4" value="1.852" spread="0.016"/>
                    <measurement group_id="O5" value="1.876" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.329</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.294</ci_lower_limit>
            <ci_upper_limit>0.364</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 5/5 QD minus Placebo QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.134</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.099</ci_lower_limit>
            <ci_upper_limit>0.169</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 5/5 QD minus Olodaterol 5 mcg QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.135</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.100</ci_lower_limit>
            <ci_upper_limit>0.170</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 5/5 QD minus Tiotropium 5 mcg QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.305</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.269</ci_lower_limit>
            <ci_upper_limit>0.340</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 2.5/5 QD minus Placebo QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.110</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.075</ci_lower_limit>
            <ci_upper_limit>0.145</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 2.5/5 QD minus Olodaterol 5 mcg QD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.076</ci_lower_limit>
            <ci_upper_limit>0.146</ci_upper_limit>
            <estimate_desc>Difference calculated as Tiotropium + olodaterol 2.5/5 QD minus Tiotropium 5 mcg QD</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From drug administration until 21 days after the last administration, up to 139 days</time_frame>
      <desc>One patient received treatment for 118 days, rather than 6 weeks, due to non-compliance with study visit requirements.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Oral inhalation of placebo, 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E2">
          <title>Olodaterol 5 µg</title>
          <description>Oral inhalation of Olodaterol fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E3">
          <title>Tiotropium 5 µg</title>
          <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E4">
          <title>Tiotropium + Olodaterol 2.5/5</title>
          <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 µg and Olodaterol 5 µg (Tiotropium: 1.25 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E5">
          <title>Tiotropium + Olodaterol 5/5</title>
          <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Cellulitis gangrenous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="218"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="219"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

